Medication info
Sitagliptin/Metformin Extended Release Tablets 50/500 mg

Sitagliptin/Metformin Extended Release Tablets 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.69mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Light blue, bi-convex oval extended-release film-coated tablets
Packaging
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 202300577 · Approved 2023.02.16 · Insurance code 645605830

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine did not dissolve completely and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). The 100/1000 mg extended-release tablet is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no history of prior antidiabetic drug therapy who cannot achieve adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Patients Who Must Not Take This Medicine). 2. Patients treated with metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. Patients who cannot achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Since any change in the treatment regimen for type 2 diabetes may alter blood glucose control, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Patients Who Must Not Take This Medicine).

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dietary and exercise therapy to assist patients with type 2 diabetes in controlling their blood sugar. Sitagliptin and metformin work together to effectively improve blood sugar levels. Therefore, this medication provides help to those who struggle with blood sugar control and plays a crucial role in diabetes management.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. Cases have been reported in which the medicine did not dissolve completely and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). The 100/1000 mg extended-release tablet is taken once daily, 1 tablet per dose. Patients taking the 50/500 mg extended-release tablet or the 50/1000 mg extended-release tablet take 2 tablets together once daily. 1. Patients not currently treated with metformin: For patients with no history of prior antidiabetic drug therapy who cannot achieve adequate blood glucose control with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Patients Who Must Not Take This Medicine). 2. Patients treated with metformin: - For patients who cannot achieve adequate blood glucose control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. - Patients who have been taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release once daily. 3. Patients who cannot achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this medicine. Since any change in the treatment regimen for type 2 diabetes may alter blood glucose control, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Patients Who Must Not Take This Medicine).

Precautions

This medication is a combination product containing sitagliptin and metformin. The sitagliptin component can rarely cause serious allergic reactions, which include anaphylaxis, angioedema, and severe skin conditions such as Stevens-Johnson syndrome. These allergic reactions may appear within the first three months of taking the medication, so if symptoms are suspected, it is important to stop taking the medication immediately and consult a doctor. Additionally, sitagliptin carries the risk of acute pancreatitis, which is inflammation of the pancreas. If abdominal pain, vomiting, or loss of appetite occur during treatment, the medication should be stopped immediately and medical attention sought. The metformin component can cause a rare side effect known as severe lactic acidosis, which can be life-threatening, therefore it should not be administered to patients with impaired kidney function or those with severe infections or dehydration. This medication should not be administered to patients with moderate to severe impaired kidney function, acute heart failure, or those scheduled for tests using contrast media. Furthermore, patients with type 1 diabetes, diabetic ketoacidosis, severe liver dysfunction, and women who are pregnant or nursing should not use this medication. Care should be taken during treatment regarding irregular meals, excessive exercise, and interactions with other medications, and it should be used cautiously in patients sensitive to excipients that may cause allergic reactions. While taking this medication, gastrointestinal disturbances, headaches, dizziness, and symptoms of hypoglycemia may occur; if these symptoms are severe or persistent, it is crucial to inform a physician. Finally, before surgery or in the event of severe infections or trauma, the medication should be temporarily discontinued, and it should be resumed once the patient's condition stabilizes.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • exfoliative skin disease
  • acute pancreatitis
  • hemorrhagic pancreatitis
  • necrotizing pancreatitis
  • lactic acidosis
  • hypoglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Light blue, bi-convex oval extended-release film-coated tablets

Package unit

Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.